Clinical trials
Immune Checkpoint Blockade clinical trials
Below are recruiting immune checkpoint blockade clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04807127Recruiting
Testing blood and lung fluid markers for lung side effects
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
Leuven, Flemish BrabantAges 18–120 - NCT06623461RecruitingPhase 2
Fecal transplant with immunotherapy for advanced melanoma
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Abbotsford British Columbia, British ColumbiaAges 18 years+ - NCT04159818RecruitingPhase 2
Adding immune treatments to improve checkpoint drug response in TNBC
This Phase 2 trial tests strategies meant to “prime” the immune system so that immune checkpoint medicines may work better in people with triple-negative breast cancer that has spread (or can’t be fully cured). You might be considered if your cancer has measurable areas that can be biopsied and you meet specific health and prior-treatment rules.
AmsterdamAges 18 years+ - NCT06548789RecruitingPhase 2
Immunotherapy plus prebiotic foods for melanoma before surgery
This study tests if eating certain prebiotic foods while receiving immunotherapy before melanoma surgery can boost your immune system and improve treatment response. Participants eat study-provided foods and receive standard immunotherapy (ipilimumab with or without nivolumab, or nivolumab with or without relatlimab).
Houston, TexasAges 18 years+ - NCT07071103RecruitingPhase 2
Low-dose radiation and immunotherapy for resistant solid tumors
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Shantou, GuangdongAges 18–80 - NCT07427186Recruiting
Studying how immunotherapy affects the immune system in early-stage cancer
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
ToulouseAges 18 years+ - NCT06514898RecruitingPhase 1
Personalized cell therapy for recurrent medulloblastoma
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
Washington D.C., District of ColumbiaAges 4–30 - NCT03514368Recruiting
Testing immune markers to track cancer treatment safety and benefit
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
ToulouseAges 18 years+ - NCT05533697RecruitingPhase 1/Phase 2
mRNA medicine with or without immunotherapy for advanced solid cancers
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Los Angeles, CaliforniaAges 12 years+ - NCT05141474RecruitingEarly Phase 1
Personalized immune cell treatment for advanced cancers after failed therapy
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
BarcelonaAges 18 years+ - NCT07103395RecruitingPhase 2
Study of chemo, radiation, and dual immunotherapy for stage 3 lung cancer
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
Guangzhou, GuangdongAges 18–75 - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT04943848RecruitingPhase 1
Vaccine plus immune treatment for newly diagnosed brain stem tumors
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
Orange, CaliforniaAges 1–18 - NCT05284539RecruitingPhase 2
Chemo plus immunotherapy for mutated advanced lung cancer
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Changsha, HunanAges 18 years+ - NCT06580574RecruitingPhase 2
Immunotherapy to save the stomach or colon from surgery
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06599619Recruiting
Study of PD1 therapy on atypical moles in melanoma patients
This trial tests if an immunotherapy drug (anti-PD1) can change atypical (dysplastic) moles in people who have had melanoma. It may help understand how these drugs affect mole cells.
Pittsburgh, PennsylvaniaAges 18 years+
Hear when a new Immune Checkpoint Blockade trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint blockade?
- Yes. Clin2 currently lists 16 recruiting immune checkpoint blockade studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint blockade trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint blockade trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.